Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 10Osteosarcoma 4Uterine Neoplasms 1Neoplasms, Connective and Soft Tissue 1Liposarcoma 1Drug-Related Side Effects and Adverse Reactions 1Chordoma 1

Interventions

Doxorubicin 3lentiviral minigene vaccine of COVID-19 coronavirus 1eltrombopag 1camrelizumab 1apatinib 1Vinorelbine 1Trabectedin 1Temozolomide 1Observation 1Methotrexate 1Irinotecan 1FANG vaccine 1Dexamethasone 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Connective and Soft Tissue × camrelizumab × Sarcoma × Clear all
NCT04910126 2021-06-02

Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Unknown
84 enrolled
Sarcoma

Sarcoma, Neoplasms, Connective and Soft Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡